Fluoxetine Effects on Neurodevelopment and Behavioral Outcomes

Fluoxetine, a selective serotonin reuptake inhibitor, is increasingly prescribed during childhood and adolescence, a period of pronounced neural plasticity. By modulating serotonergic signalling, fluoxetine can influence processes such as neurogenesis, synaptic pruning and dendritic remodelling in regions critical for emotion regulation, including the hippocampus, amygdala and prefrontal cortex. Early exposure has been linked to altered expression of neurotrophic factors, changes in receptor density and enduring shifts in stress responsivity. Behaviourally, juvenile fluoxetine treatment may reduce depressive-like symptoms in stress-exposed models yet simultaneously heighten anxiety-related behaviours at certain doses. Longitudinal outcomes encompass modifications in fear memory, reward sensitivity and cognitive flexibility, underscoring the complex balance between therapeutic benefit and potential lasting effects on brain maturation. These findings bear global significance for paediatric psychiatric practice and highlight the need for age-tailored dosing and close monitoring of developmental trajectories.

Research from Nature Portfolio

Recent studies have shown that adolescent fluoxetine exposure can produce enduring alterations in reward processing. One investigation in mice demonstrated that treatment during the adolescent window enhanced conditioned place preference for cocaine in adulthood, indicating heightened sensitivity to drug reward. This effect was absent in adults treated with the same regimen. In a separate study of female mice, juvenile fluoxetine led to a persistent anxiety-like phenotype across multiple behavioural assays; re-exposure to fluoxetine in adulthood ameliorated these anxiety measures and restored key components of hippocampal and prefrontal BDNF signalling. Together, these reports reveal that timing of SSRI intervention critically shapes long-term emotional and motivational outcomes.

Fluoxetine Effects on Neurodevelopment and Behavioral Outcomes publication trend

The graph below shows the total number of articles in fluoxetine effects on neurodevelopment and behavioral outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Selective serotonin reuptake inhibitor (SSRI): An antidepressant class that increases synaptic serotonin by blocking its presynaptic reabsorption.

Neurogenesis: The birth of new neurons, particularly in the hippocampal dentate gyrus, essential for cognitive and emotional plasticity.

Perineuronal nets (PNNs): Extracellular matrix assemblies that enwrap certain neurons, regulating synaptic stability and plasticity.

Conditioned place preference (CPP): A behavioural paradigm measuring the associative rewarding properties of drugs by preference for a drug-paired environment.

Brain-derived neurotrophic factor (BDNF): A protein supporting neuron survival, differentiation and synaptic modulation, implicated in antidepressant action.

Plasma membrane monoamine transporter (PMAT): A low-affinity, high-capacity transporter that contributes to serotonin clearance, particularly in juvenile brain regions.

References

1. Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents – systematic review and meta-analysis. Pharmacological Reports (2022).
2. Fluoxetine exposure during adolescence increases preference for cocaine in adulthood. Scientific Reports (2015).
3. Adolescent fluoxetine treatment mediates a persistent anxiety-like outcome in female C57BL/6 mice that is ameliorated by fluoxetine re-exposure in adulthood. Scientific Reports (2021).
4. The impact of chronic fluoxetine treatment in adolescence or adulthood on context fear memory and perineuronal nets. Developmental Psychobiology (2024).
5. Faster Serotonin Clearance in CA3 Region of Hippocampus and Antidepressant-like Effect of Decynium-22 in Juvenile Mice Are Putatively Linked to Increased Plasma Membrane Monoamine Transporter Function: Implications for Efficacy of Antidepressants in Juveniles. Cells (2022).